Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Assessment of β Cell Mass and Function by AIRmax and Intravenous Glucose in High-Risk Subjects for Type 1 Diabetes.

Hao W, Wookwyk A, Beam C, Bahnson HT, Palmer JP, Greenbaum CJ.

J Clin Endocrinol Metab. 2017 Dec 1;102(12):4428-4434. doi: 10.1210/jc.2017-01713.

PMID:
29040630
2.

Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis.

Chen C, Cohrs CM, Stertmann J, Bozsak R, Speier S.

Mol Metab. 2017 Jul 8;6(9):943-957. doi: 10.1016/j.molmet.2017.06.019. eCollection 2017 Sep. Review.

3.

Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials.

Nathan BM, Boulware D, Geyer S, Atkinson MA, Colman P, Goland R, Russell W, Wentworth JM, Wilson DM, Evans-Molina C, Wherrett D, Skyler JS, Moran A, Sosenko JM; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes Care. 2017 Nov;40(11):1494-1499. doi: 10.2337/dc17-0916. Epub 2017 Aug 31.

PMID:
28860125
4.

Insulitis in the pathogenesis of type 1 diabetes.

Pugliese A.

Pediatr Diabetes. 2016 Jul;17 Suppl 22:31-6. doi: 10.1111/pedi.12388. Review.

5.

Staging the progression to type 1 diabetes with prediagnostic markers.

Sosenko JM.

Curr Opin Endocrinol Diabetes Obes. 2016 Aug;23(4):297-305. doi: 10.1097/MED.0000000000000267. Review.

6.

Life and death of β cells in Type 1 diabetes: A comprehensive review.

Wilcox NS, Rui J, Hebrok M, Herold KC.

J Autoimmun. 2016 Jul;71:51-8. doi: 10.1016/j.jaut.2016.02.001. Epub 2016 Mar 24. Review.

7.

Recent advances in understanding Type 1 Diabetes.

Christoffersson G, Rodriguez-Calvo T, von Herrath M.

F1000Res. 2016 Jan 27;5. pii: F1000 Faculty Rev-110. doi: 10.12688/f1000research.7356.1. eCollection 2016. Review.

8.

Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.

Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark Å, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG.

Diabetes Care. 2015 Oct;38(10):1964-74. doi: 10.2337/dc15-1419. Review.

9.

Comparison of Metabolic Outcomes in Children Diagnosed with Type 1 Diabetes Through Research Screening (Diabetes Autoimmunity Study in the Young [DAISY]) Versus in the Community.

Chan CL, Taki I, Dong F, Hoffman M, Norris JM, Klingensmith G, Rewers MJ, Steck AK.

Diabetes Technol Ther. 2015 Sep;17(9):649-56. doi: 10.1089/dia.2015.0029. Epub 2015 Jun 3.

10.

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.

Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes Care. 2015 May;38(5):940-2. doi: 10.2337/dc14-2787. Epub 2015 Mar 10.

11.

Gender-dimorphic regulation of DJ1 and its interactions with metabolic proteins in streptozotocin-induced diabetic rats.

Chaudhari HN, Kim SW, Yun JW.

J Cell Mol Med. 2015 May;19(5):996-1009. doi: 10.1111/jcmm.12490. Epub 2015 Feb 27.

12.

β cell death and dysfunction during type 1 diabetes development in at-risk individuals.

Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, Ledizet M, Sosenko JM, Krischer JP, Palmer JP; Type 1 Diabetes TrialNet Study Group.

J Clin Invest. 2015 Mar 2;125(3):1163-73. doi: 10.1172/JCI78142. Epub 2015 Feb 2.

13.

A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history.

Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D, Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2015 Feb;38(2):271-6. doi: 10.2337/dc14-1813. Epub 2014 Dec 17.

14.

A rule-based prognostic model for type 1 diabetes by identifying and synthesizing baseline profile patterns.

Lin Y, Qian X, Krischer J, Vehik K, Lee HS, Huang S.

PLoS One. 2014 Jun 13;9(6):e91095. doi: 10.1371/journal.pone.0091095. eCollection 2014.

15.

Distribution of C-peptide and its determinants in North American children at risk for type 1 diabetes.

Xu P, Qian X, Schatz DA, Cuthbertson D, Krischer JP; DPT-1 Study Group.

Diabetes Care. 2014 Jul;37(7):1959-65. doi: 10.2337/dc13-2603. Epub 2014 Apr 23.

16.

Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes.

Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, Beam CA, Boulware DC, Matheson D, Cuthbertson D, Herold KC, Eisenbarth G, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups.

Diabetes Care. 2014 Apr;37(4):979-84. doi: 10.2337/dc13-2359. Epub 2014 Feb 18.

17.

The clinical measures associated with C-peptide decline in patients with type 1 diabetes over 15 years.

Lee TH, Kwon AR, Kim YJ, Chae HW, Kim HS, Kim DH.

J Korean Med Sci. 2013 Sep;28(9):1340-4. doi: 10.3346/jkms.2013.28.9.1340. Epub 2013 Aug 28.

18.

Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants.

Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes. 2013 Dec;62(12):4179-83. doi: 10.2337/db13-0656. Epub 2013 Jul 17.

19.

The use of intermediate endpoints in the design of type 1 diabetes prevention trials.

Krischer JP; Type 1 Diabetes TrialNet Study Group.

Diabetologia. 2013 Sep;56(9):1919-24. doi: 10.1007/s00125-013-2960-7. Epub 2013 Jun 7.

20.

Type 1 diabetes: translating mechanistic observations into effective clinical outcomes.

Herold KC, Vignali DA, Cooke A, Bluestone JA.

Nat Rev Immunol. 2013 Apr;13(4):243-56. doi: 10.1038/nri3422. Review.

Supplemental Content

Support Center